In vivo biodistribution studies involving a xenograft model of CD19+ ovarian cancer in mice demonstrated that after about 72 h, most of the free cMLVs were cleared by the liver, while those attached to NKCs had a significant presence in the circulation, lymph node, spleen, and the tumor site. The gene discussed is CD19; the disease is neoplasm.